Liang Huiyun, Salinas Richard A, Leal Belinda Z, Kosakowska-Cholody Teresa, Michejda Christopher J, Waters Stephen J, Herman Terence S, Woynarowski Jan M, Woynarowska Barbara A
Department of Radiation Oncology, University of Texas Health Science Center, IDD Building, 14960 Omicron Drive, San Antonio, TX 78245, USA.
Mol Cancer Ther. 2004 Nov;3(11):1385-96.
Irofulven (hydroxymethylacylfulvene) is a novel antitumor drug, which acts by alkylating cellular macromolecular targets. The drug is a potent inducer of apoptosis in various types of tumor cells, whereas it is nonapoptotic in normal cells. This study defined molecular responses to irofulven involving mitochondrial dysfunction and leading to death of prostate tumor LNCaP-Pro5 cells. Irofulven caused early (2-5 hours) translocation of the proapoptotic Bax from cytosol to mitochondria followed by the dissipation of mitochondrial membrane potential and cytochrome c release at 4 to 12 hours. These effects preceded caspase activation and during the first 6 hours were not affected by caspase inhibitors. Processing of caspase-9 initiated the caspase cascade at approximately 6 hours and progressed over time. The activation of the caspase cascade provided a positive feedback loop that enhanced Bcl-2-independent translocation and cytochrome c release. General and specific caspase inhibitors abrogated irofulven-induced apoptotic DNA fragmentation with the following order of potency: pan-caspase > or = caspase-9 > caspase-8/6 > caspase-2 > caspase-3/7 > caspase-1/4. Abrogation of caspase-mediated DNA fragmentation failed to salvage irofulven-treated cells from growth inhibition and loss of viability, demonstrating a substantial contribution of a caspase-independent cell death. Monobromobimane, an inhibitor of alternative caspase-independent apoptotic pathway that is mediated by mitochondrial permeability transition, antagonized both apoptosis, measured as phosphatidylserine externalization, and cytotoxicity of irofulven. Collectively, the results indicate that irofulven-induced signaling is integrated at the level of mitochondrial dysfunction. The induction of both caspase-dependent and caspase-independent death pathways is consistent with pleiotropic effects of irofulven, which include targeting of cellular DNA and proteins.
异环磷酰胺(羟甲基酰基富烯)是一种新型抗肿瘤药物,其作用机制是使细胞大分子靶点烷基化。该药物是多种肿瘤细胞凋亡的强效诱导剂,而在正常细胞中无凋亡作用。本研究确定了异环磷酰胺诱导的分子反应,涉及线粒体功能障碍并导致前列腺肿瘤LNCaP-Pro5细胞死亡。异环磷酰胺导致促凋亡蛋白Bax在早期(2 - 5小时)从细胞质转位至线粒体,随后在4至12小时线粒体膜电位消散和细胞色素c释放。这些效应先于半胱天冬酶激活,且在最初6小时不受半胱天冬酶抑制剂影响。半胱天冬酶-9的激活在大约6小时启动半胱天冬酶级联反应,并随时间进展。半胱天冬酶级联反应的激活提供了一个正反馈环,增强了不依赖Bcl-2的转位和细胞色素c释放。通用和特异性半胱天冬酶抑制剂可消除异环磷酰胺诱导的凋亡性DNA片段化,其效力顺序如下:泛半胱天冬酶≥半胱天冬酶-9>半胱天冬酶-8/6>半胱天冬酶-2>半胱天冬酶-3/7>半胱天冬酶-1/4。消除半胱天冬酶介导的DNA片段化未能使异环磷酰胺处理的细胞免于生长抑制和活力丧失,表明存在大量不依赖半胱天冬酶的细胞死亡。单溴代双硫腙是由线粒体通透性转换介导的另一种不依赖半胱天冬酶的凋亡途径的抑制剂,它拮抗了以磷脂酰丝氨酸外翻衡量的凋亡以及异环磷酰胺的细胞毒性。总体而言,结果表明异环磷酰胺诱导的信号传导在线粒体功能障碍水平整合。半胱天冬酶依赖性和非依赖性死亡途径的诱导与异环磷酰胺的多效性作用一致,异环磷酰胺的多效性作用包括靶向细胞DNA和蛋白质。